In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

M A Pfaller, R Hollis, B P Goldstein, S Messer, D Diekema, T Henkel

Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu

Journal of clinical microbiology 2010 Jul

filter terms:

The efficacy of anidulafungin, an echinocandin antifungal agent with potent anti-Candida activity, in treating esophageal candidiasis was tested in a double-blind study versus oral fluconazole. Isolates were identified and tested for susceptibility. Candida albicans represented >90% of baseline isolates. The MIC(90) of anidulafungin for all strains was 0.06 mg/liter.

Citation

M A Pfaller, R Hollis, B P Goldstein, S Messer, D Diekema, T Henkel. In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial. Journal of clinical microbiology. 2010 Jul;48(7):2613-4